Home > Keywords > Thématique > Science

Science

Articles

  • Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
    16 November 2022, by Elodie DORMES

    Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
    Emmanuelle BETTENDORF will be there as well to assist to conferences about Emerging #Oligonuleotide Therapeutics, #Delivery Strategies for Oligonucleotides, Peptides and mRNA and meet with all actors in the field.

  • Oligonucleotides for CNS Congress from February 22-24, 2021
    2 February 2021, by Elodie DORMES

    Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of Oligonucleotides”.

  • Vect-Horus will be attending the #EANM 2022 Annual Congress
    18 October 2022, by Elodie DORMES

    Great occasion to assist to valuable conferences about Nuclear Medicine, Molecular Imaging, Optimization of Radiolabeled Biomolecules in one of the most valuable Nuclear Medicine event in Europe.
    Meet with Cedric MALICET, PhD during the EANM on Oct 15-19, 2022 in Barcelona.

  • TIDES Asia, March 2-5 2021 - 100% Virtual
    4 March 2021, by Elodie DORMES

    Guillaume JACQUOT PharmD, PhD, will present last company results on extra-hepatic delivery of oligonucleotides.

  • Vect-Horus will join the Single-Domain Antibodies Summit
    14 September 2023, by Emmanuelle BETTENDORF

    Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
    Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain Antibodies engineering and structure” and of course “Single domain Antibodies in neurobiology”.
    We look forward to discussing with the scientific community attending this meeting and sharing with them our last advances in the use of nanobodies as (…)

  • mRNA Based Therapeutics poster
    3 February, by Emmanuelle BETTENDORF

    Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
    Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted (…)

  • How blood–brain barrier technology is unleashing CNS therapies
    18 March, by Emmanuelle BETTENDORF

    We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
    This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
    Click below for the full article.
    👉 (…)

  • Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022
    28 October 2020, by Elodie DORMES

    Michel KHRESTCHATISKY will be part of the roundtable 4 and will present the company latest results in connection with “Maintaining and increasing performance – intelligent human machine interfaces, brain tech, exoskeletons, human factor, psychology… ”
    You can access to the program by following the link: https://sante-espace.com/

  • Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
    27 November 2019, by Elodie DORMES

    Varini et al. J Control Release 2019
    Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

  • Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
    15 May 2024, by Emmanuelle BETTENDORF

    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
    The study showed that these vectors have the potential to improve delivery of medication to the (…)